SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : InterMune (nasdaq)ITMN

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Secret_Agent_Man who started this subject7/6/2001 8:38:52 AM
From: IRWIN JAMES FRANKEL   of 508
 
Friday July 6, 7:00 am Eastern Time
Press Release
SOURCE: InterMune, Inc.
Intermune Closes Public Offerings of $287 Million of Common Stock And Convertible Notes
BRISBANE, Calif., July 6 /PRNewswire/ -- InterMune, Inc. (Nasdaq: ITMN - news) today announced the closing of its public offering of 4,295,896 shares of common stock, including 545,896 shares issued pursuant to the underwriters' exercise in full of their over-allotment option, at a price to the public of $32.00 per share and the closing of its public offering of $149,500,000 aggregate principal amount of 5.75% convertible subordinated notes due 2006, including $19,500,000 principal amount of the notes issued pursuant to the underwriters' exercise in full of their over-allotment option. The notes are convertible into InterMune common stock at a conversion rate of approximately 26 shares per $1,000 principal amount, or $38.40 per share, subject to adjustment in certain circumstances. All of the shares and the notes were sold by InterMune.

The offering was made through an underwriter group led by Lehman Brothers Inc., with Banc of America Securities LLC, Robertson Stephens, Inc. and UBS Warburg LLC co-managing the offering.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext